In this chapter, we review the use of DMARDs in several clinical RA cohorts and databases between the 1970s and the 2000s. The DMARD profile in the QUEST-RA database provides an overview of clinical use of MTX in recent years in 25 countries. The data show that (I) MTX is currently the most frequently used DMARD in RA, and (II) that this development has taken about 20 years to emerge.

background: disease-modifying drugs (dmds) are a significant expenditure for treating multiple sclerosis (ms). however, there is limited report on assessment of the cost-utility of dmds compared with symptom management in the presence of long-term data. this study aimed to assess the lifetime cost-utility from the iranian healthcare perspectives of 4dmds relative to symptom management alone in ...

1. Distinguish between biologic DMARD use and nonbiologic DMARD use in the treatment of rheumatoid arthritis (RA). 2. Assess the differences between classes of biologic disease-modifying antirheumatic drug (DMARD) therapy. 3. Based on individual patient characteristics, construct a treatment and monitoring plan for a patient with RA and, when appropriate, include biologic DMARD therapy. 4. Just...

Therapy with disease-modifying antirheumatic drugs (DMARDs) should be started as soon as the diagnosis of rheumatoid arthritis (RA) is made. [1]The early use of DMARDs has been recommended in recent years to reduce disease progression and long-term disability. [2]The need for early use of DMARDs is incorporated in new National Institute for Health and Care Excellence (NICE) guidance. [3]Early u...

Therapy with disease-modifying antirheumatic drugs (DMARDs) should be started as soon as the diagnosis of rheumatoid arthritis (RA) is made. [1]The early use of DMARDs has been recommended in recent years to reduce disease progression and long-term disability. [2]The need for early use of DMARDs is incorporated in new National Institute for Health and Care Excellence (NICE) guidance. [3]Early u...